Literature DB >> 15701849

Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients.

Nádia Aparecida Bérgamo1, Luciana Caricati da Silva Veiga, Patricia Pintor dos Reis, Inês Nobuko Nishimoto, José Magrin, Luiz Paulo Kowalski, Jeremy A Squire, Sílvia Regina Rogatto.   

Abstract

PURPOSE: Genetic biomarkers of head and neck tumors could be useful for distinguishing among patients with similar clinical and histopathologic characteristics but having differential probabilities of survival. The purpose of this study was to investigate chromosomal alterations in head and neck carcinomas and to correlate the results with clinical and epidemiologic variables. EXPERIMENTAL
DESIGN: Cytogenetic analysis of short-term cultures from 64 primary untreated head and neck squamous cell carcinomas was used to determine the overall pattern of chromosome aberrations. A representative subset of tumors was analyzed in detail by spectral karyotyping and/or confirmatory fluorescence in situ hybridization analysis.
RESULTS: Recurrent losses of chromosomes Y (26 cases) and 19 (14 cases), and gains of chromosomes 22 (23 cases), 8 and 20 (11 cases each) were observed. The most frequent structural aberration was del(22)(q13.1) followed by rearrangements involving 6q and 12p. The presence of specific cytogenetic aberrations was found to correlate significantly with an unfavorable outcome. There was a significant association between survival and gains in chromosomes 10 (P = 0.008) and 20 (P = 0.002) and losses of chromosomes 15 (P = 0.005) and 22 (P = 0.021). Univariate analysis indicated that acquisition of monosomy 17 was a significant (P = 0.0012) factor for patients with a previous family history of cancer.
CONCLUSIONS: The significant associations found in this study emphasize that alterations of distinct regions of the genome may be genetic biomarkers for a poor prognosis. Losses of chromosomes 17 and 22 can be associated with a family history of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701849

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  PHF21B as a candidate tumor suppressor gene in head and neck squamous cell carcinomas.

Authors:  Fernanda Bernardi Bertonha; Mateus de Camargo Barros Filho; Hellen Kuasne; Patricia Pintor Dos Reis; Erika da Costa Prando; Juan José Augusto Moyano Muñoz; Martín Roffé; Glaucia Noeli Maroso Hajj; Luiz Paulo Kowalski; Claudia Aparecida Rainho; Silvia Regina Rogatto
Journal:  Mol Oncol       Date:  2014-10-13       Impact factor: 6.603

2.  Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted.

Authors:  Graham M Poage; Brock C Christensen; E Andres Houseman; Michael D McClean; John K Wiencke; Marshall R Posner; John R Clark; Heather H Nelson; Carmen J Marsit; Karl T Kelsey
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

3.  Translocation (12;14) and other chromosome abnormalities in squamous cell carcinoma of the tongue.

Authors:  Esther Manor; Sarit Tetro; Lipa Bodner
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-28       Impact factor: 2.503

4.  Loss of Y-chromosome does not correlate with age at onset of head and neck carcinoma: a case-control study.

Authors:  L C Silva Veiga; N A Bérgamo; P P Reis; L P Kowalski; S R Rogatto
Journal:  Braz J Med Biol Res       Date:  2012-01-19       Impact factor: 2.590

5.  Association between loss of Y chromosome and poor prognosis in male head and neck squamous cell carcinoma.

Authors:  Robert Hollows; Wenbin Wei; Jean-Baptiste Cazier; Hisham Mehanna; Gabriella Parry; Graham Halford; Paul Murray
Journal:  Head Neck       Date:  2018-12-23       Impact factor: 3.147

6.  Alterations of GPI transamidase subunits in head and neck squamous carcinoma.

Authors:  Wei-Wen Jiang; Marianna Zahurak; Zeng-Tong Zhou; Hannah Lui Park; Zhong-Min Guo; Guo-Jun Wu; David Sidransky; Barry Trink; Joseph A Califano
Journal:  Mol Cancer       Date:  2007-11-21       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.